C3 and systemic lupus erythematosus: In a small study including nine SLE patients with secondary nonresponse to rituximab, obinutuzumab (2000 mg) led to significant reductions in SLEDAI and BILAG scores, improved C3 and anti-dsDNA levels, and enabled the tapering of steroids in most patients [139].